secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0000950170-23-006139
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron launches APONVIE IV for PONV prevention; cites 50% fewer vomiting vs ondansetron
--------------------------------------------------------------------------------

- APONVIE (aprepitant injectable emulsion) is first IV NK1 receptor antagonist for postoperative nausea and vomiting (PONV).
- Single IV push achieves ≥97% brain receptor occupancy within 5 minutes and maintains therapeutic levels for 48 hours.
- Aprepitant reduced vomiting by ~50% in first 24 and 48 hours vs IV ondansetron in clinical trials.
- Target market: ~36 million U.S. procedures annually in high/moderate PONV risk patients; CEO sees potential for several hundred million dollars in sales.
- Launch leverages existing acute-care commercial team with no additional field force or significant external spend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023006139/0000950170-23-006139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023006139/hrtx-20230306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer